CODEXIS, INC.
CDXSNasdaq
$2.24
↑ +3.7%Jul 17 close · end-of-day
Price
1Y↓ -21.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$203.3M
Enterprise Value
$178.7M
P/E
—
P/S
2.6
P/B
4.7
EV/EBITDA
—
PEG
—
FCF Yield
-10.9%
Dividend Yield
—
Revenue (TTM)
$78.1M
Net Income (TTM)
-$32.0M
Free Cash Flow (TTM)
-$22.1M
Gross Margin
—
Operating Margin
-37.5%
Net Margin
-41.0%
ROE
-74.0%
ROIC
-124.6%
Debt / Equity
0.9
Net Cash
$24.7M
Return 1Y
-22.2%
Company profile
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company also provides biocatalyst screening and protein engineering services. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.
- CEO
- Stephen G. Dilly
- Sector
- Manufacturing
- Industry
- Chemicals
- Employees
- 250
- Headquarters
- California
- Website
- codexis.com
Management & directors
- Lutz StefanChief Scientific Officer
- Erbez GeorgiaChief Financial Officer
- Moore AlisonChief Technical Officer
Roles derived from SEC Form 4 filings.
Earnings
CDXS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15.2M↑ +102.1%
Diluted EPS-$0.10↓ -60.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $69.1M | $104.8M | $138.6M | $70.1M | $59.3M | $70.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$23.9M | -$22.7M | -$34.9M | -$68.1M | -$58.5M | -$41.7M |
| Net income | -$24.0M | -$21.3M | -$33.6M | -$76.2M | -$65.3M | -$44.0M |
| Diluted EPS | -$0.40 | -$0.33 | -$0.51 | -$1.12 | -$0.89 | -$0.50 |
| Operating cash flow | -$16.5M | -$14.3M | $11.3M | -$52.6M | -$49.4M | -$19.4M |
| Free cash flow | -$20.2M | -$28.1M | $3.0M | -$57.1M | -$53.7M | -$23.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -34.6% | -21.7% | -25.2% | -97.0% | -98.6% | -59.3% |
| Net margin | -34.8% | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0M | $12.8M | $21.5M | $7.5M | $15.3M | $8.6M | $38.9M | $15.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$22.7M | -$16.6M | -$7.3M | -$20.5M | -$12.9M | -$18.9M | $10.6M | -$8.0M |
| Net income | -$22.8M | -$20.6M | -$10.4M | -$20.7M | -$13.3M | -$19.6M | $9.6M | -$8.7M |
| Diluted EPS | -$0.32 | -$0.29 | -$0.12 | -$0.25 | -$0.16 | -$0.22 | $0.13 | -$0.10 |
| Operating cash flow | -$12.2M | -$13.0M | -$16.5M | -$13.8M | -$18.0M | -$7.7M | $20.1M | -$13.2M |
| Free cash flow | -$12.6M | -$14.0M | -$18.2M | -$15.1M | -$20.5M | -$7.9M | $19.6M | -$13.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -284.9% | -129.0% | -34.2% | -271.6% | -83.9% | -220.3% | 27.1% | -52.7% |
| Net margin | -285.2% | -160.8% | -48.4% | -274.3% | -86.6% | -228.1% | 24.7% | -57.1% |
Company news
May 11, 2026
May 8, 2026
May 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | De Vre Raymond | Sale | 2,605 | $2.37 | $6,173.85 | filing |
| 2026-02-24 | Lutz Stefan· Chief Scientific Officer | Sale | 5,862 | $1.13 | $6,641.06 | filing |
| 2026-02-06 | MOORE ALISON· President and CEO | Sale | 3,826 | $1.31 | $5,000.96 | filing |
| 2026-02-06 | Erbez Georgia· See Remarks | Sale | 3,826 | $1.31 | $5,000.96 | filing |
| 2026-02-06 | Lutz Stefan· Chief Scientific Officer | Sale | 2,492 | $1.31 | $3,257.29 | filing |
| 2026-01-07 | Lutz Stefan· CSO | Sale | 4,685 | $1.70 | $7,949.51 | filing |
| 2025-12-01 | Opaleye Management Inc. | Sale | 245,000 | $1.67 | $408,537.50 | filing |
| 2025-12-01 | Opaleye Management Inc. | Sale | 245,000 | $1.67 | $408,537.50 | filing |
| 2025-12-01 | Opaleye Management Inc. | Sale | 8,533 | $1.67 | $14,228.78 | filing |
| 2025-12-01 | Opaleye Management Inc. | Sale | 8,533 | $1.67 | $14,228.78 | filing |
| 2025-11-28 | Opaleye Management Inc. | Sale | 105,000 | $1.75 | $183,750.00 | filing |
| 2025-11-28 | Opaleye Management Inc. | Sale | 105,000 | $1.75 | $183,750.00 | filing |
| 2025-11-28 | Opaleye Management Inc. | Sale | 2,490 | $1.75 | $4,357.50 | filing |
| 2025-11-28 | Opaleye Management Inc. | Sale | 2,490 | $1.75 | $4,357.50 | filing |
| 2025-11-26 | Opaleye Management Inc. | Sale | 148,318 | $1.74 | $258,266.13 | filing |
| 2025-11-26 | Opaleye Management Inc. | Sale | 148,318 | $1.74 | $258,266.13 | filing |
| 2025-11-26 | Opaleye Management Inc. | Sale | 5,000 | $1.74 | $8,706.50 | filing |
| 2025-11-26 | Opaleye Management Inc. | Sale | 5,000 | $1.74 | $8,706.50 | filing |
| 2025-11-21 | WOLF DENNIS P | Sale | 8,952 | $1.56 | $13,988.40 | filing |
| 2025-11-13 | MOORE ALISON· President and CEO | Award | 85,000 | $0.00 | $0.00 | filing |
| 2025-11-12 | Opaleye Management Inc. | Sale | 890,000 | $1.94 | $1.7M | filing |
| 2025-11-12 | Opaleye Management Inc. | Sale | 165,000 | $1.96 | $323,730.00 | filing |
| 2025-11-12 | Opaleye Management Inc. | Sale | 27,459 | $1.94 | $53,193.57 | filing |
| 2025-11-11 | Opaleye Management Inc. | Sale | 535,000 | $1.80 | $962,679.00 | filing |
| 2025-11-11 | Opaleye Management Inc. | Sale | 535,000 | $1.80 | $962,679.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.